%0 Journal Article %1 oster_immunogenicity_2007 %A Oster, P %A O'Hallahan, J %A Aaberge, I %A Tilman, S %A Ypma, E %A Martin, D %D 2007 %J Vaccine %K Antibodies, B, Bacterial, Child, Humans, Infant, Infections, Meningococcal Neisseria New Pharmaceutical Preparations, Preschool, Safety Serogroup Vaccines, Zealand, meningitidis, %N 16 %P 3075--9 %R 10.1016/j.vaccine.2007.01.023 %T Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand %U http://www.ncbi.nlm.nih.gov/pubmed/17289223 %V 25 %X To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of \textgreater1,000,000 people under 20 years. After the three-dose course 75\% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.

@article{oster_immunogenicity_2007, abstract = {To control the devastating group B meningococcal epidemic in New Zealand a strain-specific {OMV} vaccine {(MeNZB)} was extensively tested before vaccination of {\textgreater}1,000,000 people under 20 years. After the three-dose course 75\% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. {MeNZB} was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.}, added-at = {2011-03-11T10:05:34.000+0100}, author = {Oster, P and {O'Hallahan}, J and Aaberge, I and Tilman, S and Ypma, E and Martin, D}, biburl = {https://www.bibsonomy.org/bibtex/29c2c1bfd2d1a57006d03244e338d252f/jelias}, doi = {10.1016/j.vaccine.2007.01.023}, interhash = {20ce8dcd83d6c5eb3dc26a8205cb6325}, intrahash = {9c2c1bfd2d1a57006d03244e338d252f}, issn = {{0264-410X}}, journal = {Vaccine}, keywords = {Antibodies, B, Bacterial, Child, Humans, Infant, Infections, Meningococcal Neisseria New Pharmaceutical Preparations, Preschool, Safety Serogroup Vaccines, Zealand, meningitidis,}, month = apr, note = {{PMID:} 17289223}, number = 16, pages = {3075--9}, timestamp = {2011-03-11T10:06:11.000+0100}, title = {Immunogenicity and safety of a strain-specific {MenB} {OMV} vaccine delivered to under 5-year olds in New Zealand}, url = {http://www.ncbi.nlm.nih.gov/pubmed/17289223}, volume = 25, year = 2007 }